Eculizumab

Results: 59



#Item
1Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris

Risk factors of chronic renal failure after atypical Hemolytic Uremic Syndrome under plasmatherapy Professeur Eric Rondeau Urgences néphrologiques et Transplantation rénale Hôpital Tenon, Paris

Add to Reading List

Source URL: www.hemapherese.fr

Language: English - Date: 2016-05-16 12:22:49
2HUS ParisMode de compatibilité]

HUS ParisMode de compatibilité]

Add to Reading List

Source URL: www.hemapherese.fr

Language: English - Date: 2016-05-16 12:27:10
31 INTERIM FUNDING CRITERIA IN ONTARIO FOR SOLIRIS AHUS –CASE BY CASE BASIS Initiation Criteria A patient must meet all three of the following to obtain funding for initial treatment of eculizumab for aHUS: 1. Confirmed

1 INTERIM FUNDING CRITERIA IN ONTARIO FOR SOLIRIS AHUS –CASE BY CASE BASIS Initiation Criteria A patient must meet all three of the following to obtain funding for initial treatment of eculizumab for aHUS: 1. Confirmed

Add to Reading List

Source URL: www.ahuscanada.org

Language: English - Date: 2015-03-19 14:38:28
4Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands  Alexion’s  metabolic  franchise  wi

Alexion to Acquire Synageva to Strengthen Global Leadership in Developing and Commercializing Transformative Therapies for Patients with Devastating and Rare Diseases -- Expands  Alexion’s  metabolic  franchise  wi

Add to Reading List

Source URL: www.alexion-synagevatransaction.com

Language: English - Date: 2015-05-06 06:45:36
5

PDF Document

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2015-03-23 21:11:42
6

PDF Document

Add to Reading List

Source URL: www.pbs.gov.au

Language: English - Date: 2014-10-01 21:56:23
7Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report

Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: a case report

Add to Reading List

Source URL: www.jmedicalcasereports.com

Language: English
8Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefit

Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefit

Add to Reading List

Source URL: pbs.gov.au

Language: English - Date: 2014-10-01 21:51:53
9Cognitive disorders / Geriatrics / Healthcare / Dementia / Warilla /  New South Wales / Nursing home / Medicine / Health / Aging-associated diseases

Stakeholder meeting statement Pharmaceutical Benefits Scheme listing of eculizumab (Soliris®) for atypical haemolytic uraemic syndrome A stakeholder meeting was held on 24 June 2014 to discuss the Pharmaceutical Benefi

Add to Reading List

Source URL: pbs.gov.au

Language: English - Date: 2014-10-01 21:51:53
10SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medici

SMC briefing note Scottish Medicines Consortium advice to NHSScotland Monthly briefings are produced in order to help members of the media and other interested people understand the work and advice of the Scottish Medici

Add to Reading List

Source URL: www.scottishmedicines.org.uk

Language: English